Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)

NCT06874894 | Enrolling By Invitation DMC

• 1 other identifier: CAUH 1992-002-387
• Study Type: observational
• Target: 1,021
• Locations: 1 country
• Sites: 2

Brief Summary

This study was design to investigate the efficacy and safety of NOAC therapy in Koreans

Conditions

Fibrillation, Atrial

Keywords

Atrial Fibrillation; Stroke; Bleeding

Outcome Measures

Primary Outcomes (1)

• Clinical ischemic and hemorrhagic events

  The Rate of Ischemic stroke, systemic embolism, or myocardial infarction and ISTH (International Society on Thrombosis and Hemostasis) major/minor bleeding events

  12 months

Secondary Outcomes (1)

• Clinical other events

  12 months

Other Outcomes (1)

• COVID-19 infection

  12 months

Study Arms (1)

Atrial Fibrillation

Documented AF on 12-lead ECG, Holter monitoring, or single-lead ECG recordings and biomarkers using TEG®-6S with NOAC treatment

Eligibility Criteria

• Age: 18 Months+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

AF patients with NOAC

You may qualify if:

• Patients with documented AF on 12-lead ECG, Holter monitoring, or single-lead ECG recordings are eligible for enrollment.
• Based on AF treatment Korean guideline 19, AF patients who require NOAC treatment or are currently on NOAC treatment (within the past 3 months)
• Adults aged 18 or above who have provided consent for clinical information

You may not qualify if:

• Patients with moderate or severe mitral stenosis or mechanical prosthetic valve

Sponsors & Collaborators

• Chung-Ang University Hosptial, Chung-Ang University College of Medicine: lead
• Chung-Ang University Gwangmyeong Hospital: collaborator
• Samsung Medical Center: collaborator
• Korea University Ansan Hospital: collaborator
• Kosin University Gospel Hospital: collaborator
• Keimyung University Dongsan Medical Center: collaborator
• Yuhan Corporation: collaborator

Study Sites (2)

Chung-Ang University Gwangmyeong Hospital

Gwangmyeong, South Korea

Location

Chung-Ang University Hospital

Seoul, 06973, South Korea

Location

Related Publications (1)

• Lee SH, Kim HK, Ahn JH, Kang MG, Kim KH, Bae JS, Cho SY, Koh JS, Park Y, Hwang SJ, Gorog DA, Tantry US, Bliden KP, Gurbel PA, Hwang JY, Jeong YH. Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction. Eur Heart J. 2023 May 14;44(19):1718-1728. doi: 10.1093/eurheartj/ehad088.

  PMID: 36857519 BACKGROUND

MeSH Terms

Conditions

Atrial Fibrillation; Stroke; Hemorrhage

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 12 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: March 8, 2025
• First Posted: March 13, 2025
• Study Start: May 25, 2022
• Primary Completion (Estimated): August 30, 2026
• Study Completion (Estimated): August 30, 2026
• Last Updated: December 29, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR

Locations

KR (2)